Last reviewed · How we verify
Tranexamic Acid Injectable Solution
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding.
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding. Used for Prevention and treatment of hemorrhage in patients undergoing surgical procedures, Treatment of heavy menstrual bleeding, Management of bleeding in hemophilia and other coagulation disorders.
At a glance
| Generic name | Tranexamic Acid Injectable Solution |
|---|---|
| Also known as | Cyklokapron, Cyclokapron, Lysteda, Transamin |
| Sponsor | Mount Sinai Hospital, Canada |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, which are enzymes responsible for breaking down fibrin clots. By preventing fibrin degradation, it stabilizes clots and reduces fibrinolytic activity, effectively decreasing blood loss in conditions characterized by excessive bleeding or fibrinolysis.
Approved indications
- Prevention and treatment of hemorrhage in patients undergoing surgical procedures
- Treatment of heavy menstrual bleeding
- Management of bleeding in hemophilia and other coagulation disorders
- Reduction of blood loss in trauma patients
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Nausea and vomiting
- Diarrhea
- Headache
- Visual disturbances
Key clinical trials
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Tranexamic Acid During Colonic Endoscopic Resection Procedures (PHASE4)
- TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study (EARLY_PHASE1)
- The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery (PHASE4)
- A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery (PHASE4)
- Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft (PHASE4)
- The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon Satisfaction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tranexamic Acid Injectable Solution CI brief — competitive landscape report
- Tranexamic Acid Injectable Solution updates RSS · CI watch RSS
- Mount Sinai Hospital, Canada portfolio CI